Posted in | News | Imaging | Medical Optics

Spectral Molecular Imaging and Omega Optical to Co-Develop Multispectral Imaging Endoscopes

The National Cancer Institute has awarded a new $750,000 grant to Spectral Molecular Imaging under the Small Business Innovation Research Initiative program. The initiative is a part of the federal government’s program designed to speed up the transition of key technology from the lab to the market. Spectral Molecular Imaging will receive the award through a partnership with Omega Optical.

The grant will enable the development of advanced medical endoscopic devices featuring patented multispectral imaging technology. Spectral Molecular Imaging’s Chairman and Chief Executive Officer, Daniel L. Farkas, and Omega Optical’s Director of Research, Gary Carver, are the principal investigators of the project.

The project team plans to use the fiber-optic wavelength selection equipment in the biomedical imaging applications. The collaboration of experts from biomedical and telecom industries is expected to result in earlier detection and treatment of cancer and other disease conditions.

The program primarily aims at developing a prototype multispectral endoscope and its subsequent preclinical testing. The project is scheduled to be completed in the next two years. The preclinical testing will be conducted at the Los Angeles-based Cedars-Sinai Medical Center.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.